50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Chronic Myeloid Leukemia

Sunday, December 7, 2008: 6:00 PM-8:00 PM

Hall A (Moscone Center)

Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib

Alfonso Quintas-Cardama, MD¹, Hagop M. Kantarjian, MD²^*, Susan O'Brien, M.D.³^*, Gautam Borthakur⁴, Srdan Verstovsek⁵, William Wierda⁶, Jenny Shan⁶^* and Jorge Cortes, MD⁵

¹Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
²Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁵M.D. Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX

2111

Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy

Alfonso Quintas-Cardama, MD¹, Hagop M. Kantarjian²^*, Gautam Borthakur, MD³^*, Stefan Faderl, MD², Guillermo Garcia-Manero, MD⁴, William G. Wierda⁵^*, Elizabeth M Burton⁶^* and Jorge Cortes⁵^*

¹Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
²M.D. Anderson Cancer Center, Houston, TX
³Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁴Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Dept. of Leukemia, MD Anderson Cancer Ctr., Houston, TX

2112

Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib

Alfonso Quintas-Cardama, MD¹, Hagop M. Kantarjian²^*, Susan O'Brien, M.D.³, Farhad Ravandi, MBBS⁴, Alessandra Ferrajoli⁵, Guillermo Garcia-Manero, MD⁶^* and Jorge Cortes, MD²

¹Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
²M.D. Anderson Cancer Center, Houston, TX
³Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
⁵Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
⁶Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX

2113

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response

Susan Branford¹, Rebecca Lawrence¹^*, Andrew Grigg², John Francis Seymour, MBBS³, Anthony Schwarer⁴, Christopher Arthur⁴, Zbigniew Rudzki¹^* and Timothy Hughes¹

¹Institute of Medical & Veterinary Science, Adelaide, Australia
²Med. Onc./Hem., Royal Melbourne Hospital, Melbourne, Australia
³Peter MacCallum Cancer Institute, Richmond, Australia
⁴Australasian Leukaemia & Lymphoma Group, Australia

2114

Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy

Alfonso Quintas-Cardama, MD¹, Don L. Gibbons, M.D., Ph.D.¹^*, Hagop M. Kantarjian, MD²^*, Moshe Talpaz³, Nicholas Donato, PhD⁴ and Jorge Cortes, MD⁵

¹Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
²Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Comprehensive Cancer Ctr., Univ. of Michigan, Ann Arbor, MI
⁴Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
⁵Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX

2115

Acquired Imatinib Resistance in CML Is Associated with TKD Mutations of the BCR-ABL Fusion Gene and/or Additional Chromosomal Aberrations: Certain TKD Mutations but Not TP53 Mutations Are Associated with Chromosome Instability

Susanne Schnittger, PhD, Frank Dicker, PhD, Wolfgang Kern, MD^*, Torsten Haferlach, MD^* and Claudia Haferlach, MD

MLL Munich Leukemia Laboratory GmbH, Munich, Germany

2116

Retention but Significant Reduction of BCR-ABL Transcript in Hematopoietic Stem Cells in Chronic Myelogenous Leukemia after Imatinib Therapy

Akihiro Abe, MD, PhD¹, Yosuke Minami, MD, PhD¹^*, Kunio Kitamura, MD, PhD²^*, Fumihiko Hayakawa, MD, PhD¹^*, Yuka Nomura¹^*, Makoto Murata, MD, PhD¹^*, Akira Katsumi, MD, PhD¹^*, Hitoshi Kiyoi, MD, PhD³^*, Catriona H.M. Jamieson, MD, PhD⁴^*, Jean Y.J. Wang, PhD⁴^* and Tomoki Naoe, MD, PhD¹^*

¹Hematology and Oncology, Nagoya Univ., Nagoya, Japan
²Department of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan
³Department of Infectious Disease, Nagoya Univ., Nagoya, Japan
⁴Deapartment of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA

2117

Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy

Eric Lippert¹^*, Sophy Laibe²^*, Marie-Joelle Mozziconacci³^*, Carine Gervais⁴^*, Stéphane Girault⁵^*, Nathalie Gachard⁶^*, Isabelle Tigaud⁷^*, Nicole Dastugue⁸^*, Francoise Huguet⁹^*, Marie-Pierre Fort¹⁰^*, Virginie Eclache¹¹^* and Francois-Xavier Mahon¹²^*

¹HÃ©matopoÃ¯ése leucÃ©mique, UniversitÃ© Victor Segalen, Bordeaux, France
²Département de Biopathologie, Institut Paoli Calmettes, Marseille, France
³IPC, Marseille, Marseille, France
⁴Laboratoire d'Hématologie, Hopitaux universitaires de Strasbourg, Strasbourg, France
⁵Service d'Hématologie Clinique, Hôpital Dupuytren, Limoges, France
⁶Hopital de Limoges
⁷Laboratoire de Cytogénétique, Centre Hospitalier Lyon Sud, Lyon, France
⁸Laboratoire d'Hématologie, Hôpital Purpan, Toulouse, France
⁹CHU de Toulouse, Toulouse, France
¹⁰Recherche Clinique, Institut Bergonie, Bordeaux, France
¹¹Laboratoire d'hématologie, Hôpital Avicenne, Bobigny, France
¹²HÃ©matopoÃ¯ése leucÃ©mique, UniversitÃ© Victor Segalen INSERM U876, Bordeaux, France

2118

Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year

Simona Soverini¹^*, Alessandra Gnani²^*, Sabrina Colarossi²^*, Fausto Castagnetti²^*, Francesca Palandri²^*, Stefania Paolini²^*, Cristina Papayannidis²^*, Antonella Gozzini³^*, Valeria Santini³^*, Daniela Cilloni⁴, Ester Orlandi⁵^*, Serena Merante⁵^*, Franca Radaelli⁶^*, Michela Rondoni⁷^*, Michele Malagola⁸^*, Angela Poerio²^*, Marilina Amabile²^*, Ilaria Iacobucci²^*, Gabriele Gugliotta²^*, Gianantonio Rosti²^*, Giovanni Martinelli²^* and Michele Baccarani²^*

¹Department of Hematology/Oncology “L. and A. Seràgnoli”, University of Bologna, Bologna, Italy
²Department of Hematology and Oncological Sciences "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
³Hematology, University of Florence, Florence, Italy
⁴Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
⁵Hematology, San Matteo, Pavia, Italy
⁶Hematology Unit, Milano
⁷Haematology Department, University of Siena, Siena, Italy
⁸Chair of Hematology, University of Brescia, Brescia, Italy

2119

The Use of 2^ndgeneration Tyrosine Kinase Inhibitors (TKI) after Failure to 2 Prior TKI: Long-Term Follow-up

Ravin Jain Garg, M.D.¹, Hagop M Kantarjian², Susan O'Brien, M.D.³, Alfonso Quintas-Cardama, MD⁴, Stefan Faderl, MD⁵, Zeev Estrov, MD⁶ and Jorge Cortes, MD⁵

¹Hematology and Oncology Fellow, M.D. Anderson Cancer Center, Houston, TX
²The University of Texas M. D. Anderson Cancer Center, Houston, TX
³Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
⁴Medical Oncology, UT MD Anderson Cancer Center, Houston, TX
⁵M.D. Anderson Cancer Center, Houston, TX
⁶Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX

2120

Stem Cell Transplant (SCT) for Patients (pts) with Chronic Myeloid Leukemia (CML) Resistant to Tyrosine Kinase Inhibitors (TKI) with BCR-ABL Kinase Domain (KD) Mutation T315I

Nikolai Velev¹^*, Jorge Cortes¹, Richard Champlin², Hagop M. Kantarjian¹, Gabriela Rondon², Sergio Giralt², Gautam Borthakur¹ and Marcos De Lima²

¹Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

2121

Imatinib Discontinuation Following a Major Molecular Response: Impact of Interferon Alpha and Leukemia Stem Cell Burden (The STOP Study)

Perttu Koskenvesa, MD¹^*, Satu Mustjoki, MD, PhD¹, Anu Räsänen, MD²^*, Mirja Vapaatalo, MD³^*, Kari Remes, MD, PhD⁴^*, Tuija Lundán, MSc, PhD⁵^*, Jukka Vakkila, MD, PhD⁶^*, Bengt Simonsson, MD, PhD⁷ and Kimmo Porkka, MD, PhD¹

¹Hematology Research Unit, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
²Department of Hematology, Kymenlaakso Central Hospital, Kotka, Finland
³Department of Hematology, Hyvinkää Hospital, Hyvinkää, Finland
⁴Department of Medicine, Turku University Central Hospital, Turku, Finland
⁵Hematology Research Unit, Department of Medicine and Laboratory of Molecular Pathology, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
⁶Department of Immunology, Haartman Institute, University of Helsinki, Finland
⁷On behalf of the Nordic CML Study Group, University Hospital, Uppsala, Sweden

2122

The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with Imatinib Plasma Levels

Ai Leen Ang, MBBS¹^*, Zhen Ping Wang, PhD²^*, Li Yi Yang, BSc¹^*, Vallalan Natesan, MSc¹^*, Michelle Poon, MBBS³^*, Liang Piu Koh, MBBS³^*, Yeow Tee Goh, MBBS¹^*, Balram Chowbay, PhD²^* and Charles Chuah, MBChB, MD⁴^*

¹Hematology, Singapore General Hospital, Singapore, Singapore
²Clinical Pharmacology, National Cancer Centre, Singapore, Singapore
³Hematology/Oncology, National University Hospital, Singapore, Singapore
⁴Hematology, Singapore General Hospital/Duke-NUS Graduate Medical School, Singapore, Singapore

2123

Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation

Joerg Hasford¹^*, Michael Lauseker²^*, Insa Gathmann³^*, Markus Pfirrmann, PhD¹^*, Richard A. Larson, MD⁴, François Guilhot⁵, Stephen G O'Brien⁶^*, Brian J. Druker⁷, Ruediger Hehlmann⁸, Andreas Hochhaus, MD⁹, For the IRIS Study Group¹⁰^* and For the German CML Study Group¹¹^*

¹IBE, München, Germany
²IBE Munich, München, Germany
³Novartis Pharma AG, Basel, Switzerland
⁴University of Chicago, Chicago, IL
⁵Clinical Investigational Centre INSERM 802, CHU Poitiers, Poitiers, France
⁶University of Newcastle, Newcastle, United Kingdom
⁷Oregon Health & Science University Cancer Institute, Portland, OR
⁸Dept. of Hematology/Oncology, University of Heidelberg, Mannheim, Germany
⁹Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
¹⁰Oregon Health & Science University Cancer Institute
¹¹Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany

2124

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization

Vijay Modur, MD, PhD¹^*, Dean C Bottino, PhD²^*, Susan Branford, PhD³, Tillmann Krahnke, PhD⁴^*, Fabrizio Pane, MD⁵, Marc Rudoltz, MD⁶, Yu Jin⁶^*, Timothy P Hughes, MD³^*, Dong-Wook Kim, MD, PhD⁷, Jerald Radich, MD⁸ and J. Carl Barrett, PhD¹^*

¹Oncology Biomarkers and Clinical Imaging, Novartis Institute of Biomedical Research Inc., Cambridge, MA
²Modeling & Simulation, Novartis Pharmaceuticals, Inc., East Hanover, NJ
³Institute of Medical and Veterinary Science, Adelaide, Australia
⁴Biostatistics and Statistical Reporting, Novartis Pharma AG, Basel, Switzerland
⁵Hematology Unit - CEINGE and Dip. di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, Italy, 80131, University of Naples, Napoli, Italy
⁶Novartis Pharmaceutical, Inc., Florham Park, NJ
⁷Hematology, St. Mary's Hospital, Seoul, South Korea
⁸Fred Hutchinson Cancer Research Center, Seattle, WA

2125

Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies

Dushyant Verma, MD, FACP, Hagop M. Kantarjian, MD, Mary Beth Rios, Susan O'Brien, MD, Pat Ault^*, Elizabeth M. Burton^*, Zeev Estrov, MD, Gautam Borthakur, MD, Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS and Jorge Cortes, MD

M.D. Anderson Cancer Center, Houston, TX

2126

Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction

Weigang Tong, M.D., Ph.D.¹, Hagop Kantarjian, M.D.¹^*, Susan O'Brien, M.D.¹, Stefan Faderl, MD², Farhad Ravandi, MBBS¹, William G Wierda, M.D., Ph.D.¹^*, Steven Kornblau, M.D.¹^*, Gautam Borthakur, M.D.¹^*, Guillermo Garcia-Manero, M.D.¹^*, Elizabeth Burton¹^*, Mary Beth Rios¹^* and Jorge Cortes, M.D.¹^*

¹Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
²M.D. Anderson Cancer Center, Houston, TX

2127

Kinetics of BCR-ABL Mutant Clones Determines Resistance in CML on Second Generation TKI Treatment

Franz X Gruber, MD¹^*, Thomas Ernst, MD²^*, Jaqueline Maier, PhD³^*, Martin C. Müller, MD⁴^*, Ingvild Mikkola, PhD¹^*, Kimmo Porkka, MD, PhD⁵, Dietger Niederwieser⁶^*, Andreas Hochhaus, MD⁷ and Thoralf Lange, MD⁸^*

¹Institute of Pharmacy, University of Tromsø, Tromsø, Norway
²Wessex Regional Genetics Laboratory, University of Southampton, Salisbury, United Kingdom
³Department of Hematology/Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany
⁴Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany
⁵Hematology Research Unit, Department of Medicine, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland
⁶Department of Hematology/Oncology and Hemostasiology, University of Leipzig, Germany
⁷Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany
⁸Hematology & Oncology, Medical Center University of Leipzig, Leipzig, Germany

2128

Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Delong Liu, MD, PhD¹^*, Yousif Matloub²^*, Jaydip Mukhopadhyay²^*, David Liu²^* and Stuart L Goldberg³

¹New York Medical College, Valhalla, NY
²Bristol-Myers Squibb, Wallingford, CT
³John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

2129

Inhibition of BCR/ABL-T315I by Dismantling the Hydrophobic Spine

Mohammad Azam, PhD¹^*, Markus Seeliger²^*, John T Powers³^*, Nathanael Gray¹^*, John Kuriyan, Ph.D.²^* and George Q. Daley, MD, PhD³

¹Biological chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA
²Stanley Hall, QB3, 508B, Molecular & Cellular Biology, Berkeley, CA
³Children's Hospital Boston, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

Chronic Myeloid Leukemia - Therapy Poster II